Invivo Capital Partners
Signal active
Investment Firm
Overview
Invivo Capital is a team of knowledgeable professionals with the scientific, technical, and financial know-how required to analyze and make investments that provide value to the invested company. They also have a network of contacts and key strategic relationships in the health ecosystem.
Highlights
Founded
2019
Industry
Venture Capital
Employees
1-10
Investment
16
Lead Investment
8
Exits
undefined
Stages
Early Stage Venture, Seed
Investor Type
Venture Capital
Location
Barcelona, Catalonia, Spain, Europe
Contact Information
Social
Profile Resume
Invivo Capital Partners, established in 2019 and headquartered in Europe., specializes in Early Stage Venture, Seed investments across Biotechnology, Pharmaceutical, Therapeutics, Financial Services, Venture Capital, Finance, Life Science, Medical, Angel Investment, Health Care. Their recent investments include EsoBiotec, Corteria Pharmaceuticals, Omnes Capital, Jeito Capital, OrbiMed. The highest investment round they participated in was $12.1B. Among their most notable exits are EsoBiotec and Corteria Pharmaceuticals. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Invivo Capital Partners has made 16 investments. Their most recent investment was on Dec 12, 2023, when EsoBiotec raised $2.2M.
investments
16
Diversity investments
0
Lead investments
8
Number of exits
undefined
Investments
16
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| May 03, 2023 | ARTHEx Biotech | Biotechnology | 46.5M |
| Jun 22, 2023 | OneChain Immunotherapeutics | Biotechnology | 7.3M |
| Sep 07, 2023 | Corteria Pharmaceuticals | Biotechnology | 69.5M |
| Dec 12, 2023 | EsoBiotec | Biotechnology | 2.2M |
Exits
0
Funding Timeline
Funding rounds
16
Investors
1
Funds
1
Funding Rounds
16
Invivo Capital Partners has raised 16 rounds. Their latest funding was raised on Dec 12, 2023 from a Series A - EsoBiotec round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| May 03, 2023 | Series B - ARTHEx Biotech | - | 46.5M | - |
| Jun 22, 2023 | Seed Round - OneChain Immunotherapeutics | - | 7.3M | - |
| Sep 07, 2023 | Series A - Corteria Pharmaceuticals | - | 69.5M | - |
| Dec 12, 2023 | Series A - EsoBiotec | - | 2.2M | - |
Investors
1
Invivo Capital Partners is funded by 1 investor(s). Barcelona Ventures Kantor is the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
Barcelona Ventures | No | Angel Round - Invivo Capital Partners | 1.2M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
Funding Round
Dec 12, 2023
EsoBiotec raised $2159699 on 2023-12-12 in Series A
Funding Round
Sep 07, 2023
Corteria Pharmaceuticals raised $69538574 on 2023-09-07 in Series A
Funding Round
Jun 22, 2023
OneChain Immunotherapeutics raised $7340197 on 2023-06-22 in Seed Round
Funding Round
May 03, 2023
ARTHEx Biotech raised $46487689 on 2023-05-03 in Series B
Funding Round
Sep 19, 2022
Atekka raised $4914803 on 2022-09-19 in Venture Round